Log In
Print this Print this

Darleukin (L19-IL2)

  Manage Alerts
Collapse Summary General Information
Company Philogen S.p.A.
DescriptionFusion protein consisting of the human vascular targeting antibody L19 and IL-2
Molecular Target Interleukin-2 (IL-2)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today